|
Source
Oral Presentation. 2005 Proceedings of the American Society of Clinical
Oncology Meeting, Orlando, Florida. No abstract available
Purpose
- Evaluate the addition of the anti-VEGF bevacizumab to paclitaxel as
first-line therapy in patients with metastatic breast cancer
Patients and methods
- 715 patients without prior chemotherapy for metastatic breast cancer
enrolled
– 350 patients received paclitaxel 90 mg/m2 qwk
– 365 patients received paclitaxel + bevacizumab 10 mg/kg q2wk
- HER2-positive only if prior treatment with or contraindication
to trastuzumab
- Adjuvant taxane only if disease-free interval >12 months
- No therapeutic anticoagulation, no CNS metastases
Results
Results
SELECT PUBLICATIONS
Burstein HJ et al. Metronomic chemotherapy with and without bevacizumab for
advanced breast cancer: A randomized phase II study. San Antonio Breast Cancer
Symposium 2005;Abstract 4.
Cobleigh MA et al. A phase I/II dose-escalation trial of bevacizumab in previously
treated metastatic breast cancer. Semin Oncol 2003;30(5 Suppl 16):117-24. Abstract
Drevs J et al. Antiangiogenic potency of various chemotherapeutic drugs for metronomic
chemotherapy. Anticancer Res 2004;24(3a):1759-63. Abstract
Hampton T. Monoclonal antibody therapies shine in breast cancer clinical trials. JAMA 2005;293(24):2985-9. No abstract available
Hudis CA. Clinical implications of antiangiogenic therapies. Oncology (Williston Park) 2005;19(4 Suppl 3):26-31. Abstract
Ignoffo RJ. Overview of bevacizumab: A new cancer therapeutic strategy targeting
vascular endothelial growth factor. Am J Health Syst Pharm 2004;61(21 Suppl 5):21-6.
Abstract
Martel CL et al. Incidence of bevacizumab (BE) related toxicities: Association of hypertension
(HTN) and proteinuria (PTN), a BE toxicity syndrome (BETS). Proc ASCO 2005;Abstract 8062.
Miller KD. Recent translational research: Antiangiogenic therapy for breast cancer —
Where do we stand? Breast Cancer Res 2004;6(3):128-32. Abstract
Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab
as first-line therapy for locally recurrent or metastatic breast cancer: A trial
coordinated by the Eastern Cooperative Oncology Group (E2100). San Antonio Breast
Cancer Symposium 2005;Abstract 3.
Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab
plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9. Abstract
Miller KD, Dul CL. Breast cancer: The role of angiogenesis and antiangiogenic therapy. Hematol Oncol Clin North Am 2004;18(5):1071-86, ix. Abstract
Morabito A et al. Antiangiogenic strategies, compounds, and early clinical results in
breast cancer. Crit Rev Oncol Hematol 2004;49(2):91-107. Abstract
Moses MA et al. A role for antiangiogenic therapy in breast cancer. Curr Oncol Rep 2004;6(1):42-8. Abstract
Ramaswamy B, Shapiro CL. Phase II trial of bevacizumab in combination with docetaxel
in women with advanced breast cancer. Clin Breast Cancer 2003;4(4):292-4. No
abstract available
Rhee J, Hoff PM. Angiogenesis inhibitors in the treatment of cancer. Expert Opin
Pharmacother 2005;6(10):1701-11. Abstract
Rugo HS. Bevacizumab in the treatment of breast cancer: Rationale and current data. Oncologist 2004;9(Suppl 1):43-9. Abstract
Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol 2005;23(8):1782-90. No
abstract available
Skillings JR et al. Arterial thromboembolic events (ATEs) in a pooled analysis of 5
randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. Proc
ASCO 2005;Abstract 3019.
Traina TA et al. A feasibility study of an aromatase inhibitor (AI), letrozole (L) and the
antibody to vascular endothelial growth factor (VEGF), bevacizumab (B), in patients
(pts) with hormone receptor-positive metastatic breast cancer (MBC). Proc ASCO 2005;Abstract 796.
|
